Wilex AG has reported the successful completion of a Phase 1 study in volunteers of a small molecule inhibitor of the MEK signalling pathway. MEK inhibition is being studied by a number of companies and institutions as a potential anti-cancer agent. ---Subscribe to MedNous to access this article--- Research & University News Regulation & Policy Company News
